Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease

Abstract

ObjectivesA randomized, parallel controlled, open-label clinical trial was conducted to evaluate the effect of a botanic compound berberine (BBR) on NAFLD.MethodsA randomized, parallel controlled, open-label clinical trial was conducted in three medical centers (NIH Registration number: NCT00633282). A total of 184 eligible patients with NAFLD were enrolled and randomly received (i) lifestyle intervention (LSI), (ii) LSI plus pioglitazone (PGZ) 15mg qd, and (iii) LSI plus BBR 0.5g tid, respectively, for 16 weeks. Hepatic fat content (HFC), serum glucose and lipid profiles, liver enzymes and serum and urine BBR concentrations were assessed before and after treatment. We also analyzed hepatic BBR content and expression of genes related to glucose and lipid metabolism in an animal model of NAFLD treated with BBR.ResultsAs compared with LSI, BBR treatment plus LSI resulted in a significant reduction of HFC (52.7% vs 36.4%, p = 0.008), paralleled with better improvement in body weight, HOMA-IR, and serum lipid profiles (all p<0.05). BBR was more effective than PGZ 15mg qd in reducing body weight and improving lipid profile. BBR-related adverse events were mild and mainly occurred in digestive system. Serum and urine BBR concentrations were 6.99ng/ml and 79.2ng/ml, respectively, in the BBR-treated subjects. Animal experiments showed that BBR located favorably in the liver and altered hepatic metabolism-related gene expression.ConclusionBBR ameliorates NAFLD and related metabolic disorders. The therapeutic effect of BBR on NAFLD may involve a direct regulation of hepatic lipid metabolism.Trial RegistrationClinicalTrials.gov NCT00633282

Antimicrobial Natural Product Berberine Is Efficacious for the Treatment of Atrial Fibrillation

“…In addition, there were no serious adverse events recorded during the 12-month berberine treatment. This result was consistent with another clinical trial with a higher berberine daily dose of 1.5 g for 16 weeks, in which minor adverse events such as anorexia, upset stomach, diarrhea, and constipation were recorded, but no serious adverse events such as heart failure, bone fractures, and liver toxicity were observed [12]. Nevertheless, our retrospective setting limited the choice of variables to record for analysis.…”

Berberine and barberry (Berberis vulgaris): A clinical review

“…has decreased the content of hepatic fat, probably via decreasing serum levels of ceramide and ceramide‐1‐phosphate in 41 patients with nonalcoholic fatty liver disease after 16 weeks of treatment (Chang et al, ). Another randomized, parallel‐controlled, open‐label clinical trial was conducted by Yan et al () also showed that berberine treatment (0.5 g t.i.d., for 16 weeks) resulted in a significant reduction of hepatic fat content. Similarly, a randomized, open, controlled clinical trial in 184 patients with NAFLD showed that administration of berberine (0.5 g t.i.d.)…”

Pretreatment with a combination of ligustrazine and berberine improves cardiac function in rats with coronary microembolization

“…Both ligustrazine and berberine are the component of Chinese herbs that have been used for more than two decades for the treatment of atherosclerotic and inflammatory diseases [26][27][28][29] . Our study demonstrated that ligustrazine alone improved cardiac function in CME rats, as evidenced by an increased +dp/dt max , decreased LVEDP, and decreased serum CK-MB level.…”